JAZZ Jazz Pharmaceuticals plc - Ordinary Shares
NASDAQ · Pharmaceuticals · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 3, 2026
$235.67
· of 52w range
· above low
· to high
$128.8052w low
$266.3852w high
Market Cap (MRQ)
$15.27B
P/E (TTM)
16.1
EPS (TTM)
$14.63
Revenue (TTM)
$4.60B
your badges
52W Range
$129–$266
Analyst Rating
BUY
Price Target
$294
P/E
16.1
ROE
22.1%
Net Profit Margin
20.4%
Your badge strip is empty — pin a metric anywhere on this page.
JAZZ Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$235.67
Market Cap (MRQ)
$15.27B
P/E (TTM)
16.1
EPS (TTM)
$14.63
Revenue (TTM)
$4.60B
ROE (TTM)
22.1%
Debt/Equity (MRQ)
0.9
52W Range
$129–$266
JAZZ Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
About Jazz Pharmaceuticals plc - Ordinary Shares Company overview from Wikipedia
Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).
Company history and acquisitions
2010–2019
On 18 February 2010, the FDA accepted a new drug application for JZP-6 (Sodium oxybate) for the treatment of Fibromyalgia. In the following December, a new patent was issued for Sodium Oxybate.
On September 19, 2011, Jazz Pharmaceuticals merged with Irish Azur Pharma plc to form Jazz Pharmaceuticals plc. The Azur Pharma seat in Dublin became the headquarters of the combined company. Azur Pharma had been marketing specialty pharmaceutical products in the central nervous system (CNS) and women's health areas with US operations in Philadelphia.
On 26 April 2012, the company acquired EUSA Pharma for $650 million (plus $50 million in milestone payments). In September, the company sold its Women's Health business to Meda for $95 million. In December, the company began clinical trial of intravenous Erwinaze in patients with Acute Lymphoblastic Leukemia.
In January 2014, the company announced it would acquire the rare disease drug developer Gentium SpA and its lead product Defitelio for $1 billion.
In May 2016, the company announced it would acquire Alizé Pharma II for $20.5 million. At the end of the same month, the company announced its then largest acquisition, with the purchase of Celator Pharmaceuticals for $1.5 billion. As a result, Jazz obtained the rights to breakthrough therapy Vyxeos (liposomal daunorubicin and cytarabine) for treatment of acute myeloid leukemia.
In August 2019, the company announced it would acquire Cavion Inc. for up to $310 million.
2020–present
In January 2021, Jazz announced it would acquire cannabis-focused medicinal drug company GW Pharmaceuticals for US$7.2 billion. This acquisition added the medication Epidiolex (cannabidiol), developed to treat severe epilepsy syndromes, to the company's portfolio.
In November 2025, Jazz Pharmaceuticals announced positive results from its Phase 3 trial for its cancer drug, Ziihera, a potential treatment for advanced gastroesophageal cancer.
Acquisition history
The following is an illustration of the company's mergers, acquisitions, spin-offs and historical predecessors:
== References ==
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
sectorHealthcare
industryPharmaceuticals
employees2,890
countryIE
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$4.27B2016-12-31 → 2025-12-31
EPS$-5.842016-12-31 → 2025-12-31
Net margin20.4%
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | JAZZ | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | 16.15Y avg ≈-12.5 | ≈-12.5 | · | · | |
| P/S (TTM) | 3.3 | · | · | · | |
| P/B (MRQ) | 3.2 | · | · | · | |
| Price / FCF (TTM) | 9.6 | · | · | · | |
| Price / Cash Flow (TTM) | 9.2 | · | · | · | |
| Price / Tangible Book (MRQ) | 19.8 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | JAZZ | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | 19.5% | · | · | · | |
| Pretax Margin (TTM) | 15.8% | · | · | · | |
| Net Profit Margin (TTM) | 20.4% | · | · | · | |
| ROA (TTM) | 8.5% | · | · | · | |
| ROE (TTM) | 22.1% | · | · | · |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | JAZZ | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity (MRQ) | 0.9 | · | · | · | |
| Current Ratio (MRQ) | 1.8 | · | · | · | |
| Long-Term Debt / Equity (MRQ) | 0.7 | · | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | JAZZ | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 4.9%5Y avg ≈13.0% | ≈13.0% | · | · | |
| Revenue CAGR 3Y | 5.3%5Y avg ≈10.8% | ≈10.8% | · | · | |
| Revenue CAGR 5Y | 12.5% | · | · | · | |
| EPS YoY | 41.8% | · | · | · | |
| Net Income YoY | 35.0% | · | · | · | |
| EPS CAGR 3Y | 13.1% | · | · | · | |
| Net Income CAGR 3Y | 20.2% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | JAZZ | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue / Employee | ≈$1.5M | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-1.6%
Next Report
Nov 03, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 3, 2026 | $5.71 | $6.30 | -9.4% |
| March 31, 2026 | $6.34 | $4.66 | 36.1% | |
| Dec. 31, 2025 | $6.64 | $6.65 | -0.11% | |
| Sept. 30, 2025 | $8.13 | $6.04 | 34.7% | |
| June 30, 2025 | $-8.25 | $-7.76 | -6.4% | |
| March 31, 2025 | $1.68 | $4.75 | -64.6% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B | $1.32B | $1.17B | |
| R&D Expense | · | · | · | · | · | · | $300M | $227M | $198M | $162M | $135M | $85M | |
| SG&A Expense | $1.81B | $1.39B | $1.34B | $1.42B | $1.45B | $854M | $737M | $684M | $544M | $503M | $449M | $406M | |
| Operating Expenses | $4.70B | $3.35B | $3.26B | $3.72B | $2.92B | $1.99B | $1.63B | $1.28B | $1.09B | $896M | $817M | $977M | |
| Operating Income | $-430M | $717M | $579M | $-66M | $170M | $378M | $532M | $615M | $529M | $592M | $508M | $196M | |
| Interest Income | $86M | $106M | $65M | $12M | $2M | $11M | $20M | $17M | $4M | · | · | · | |
| Other Non-op | · | · | · | · | · | · | · | · | · | · | $1M | $9M | |
| Pretax Income | $-628M | $470M | $298M | $-373M | $-113M | $275M | $454M | $529M | $441M | $532M | $436M | $152M | |
| Income Tax | $-272M | $-91M | $-120M | $-159M | $216M | $34M | $-73M | $80M | $-48M | $135M | $106M | $94M | |
| Net Income | $-356M | $560M | $415M | $-224M | $-330M | $239M | $523M | $447M | $488M | $397M | $330M | $58M | |
| EPS (Basic) | $-5.84 | $9.06 | $6.55 | $-3.58 | $-5.52 | $4.28 | $9.22 | $7.45 | $8.13 | $6.56 | $5.38 | $0.98 | |
| EPS (Diluted) | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 | $5.23 | $0.93 | |
| Shares (Basic) | 60,981,000 | 61,838,000 | 63,291,000 | 62,539,000 | 59,694,000 | 55,712,000 | 56,749,000 | 59,976,000 | 60,018,000 | 60,500,000 | 61,232,000 | 59,746,000 | |
| Shares (Diluted) | 60,981,000 | 66,007,000 | 72,066,000 | 62,539,000 | 59,694,000 | 56,517,000 | 57,550,000 | 61,221,000 | 61,317,000 | 61,870,000 | 63,036,000 | 62,614,000 |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.39B | $2.41B | $1.51B | $881M | $591M | $1.06B | $637M | $310M | $386M | $366M | $989M | $684M | |
| Receivables | $831M | $717M | $706M | $651M | $563M | $396M | $356M | $264M | $224M | $234M | $210M | $186M | |
| Inventory | $417M | $480M | $597M | $714M | $1.07B | $95M | $79M | $53M | $43M | $34M | $19M | $30M | |
| Prepaid Expense | $152M | $177M | $185M | $92M | $131M | $62M | $39M | $25M | $23M | $25M | $21M | $13M | |
| Other Current Assets | $324M | $262M | $321M | $267M | $252M | $152M | $79M | $68M | $77M | $29M | $19M | $21M | |
| Current Assets | $4.17B | $4.63B | $3.44B | $2.61B | $2.61B | $2.84B | $1.63B | $1.23B | $968M | $748M | $1.26B | $1.02B | |
| PP&E (Net) | · | · | · | · | · | $128M | $132M | $200M | $170M | $107M | $86M | $58M | |
| PP&E (Gross) | · | · | · | · | · | $196M | $187M | $250M | $211M | $140M | $109M | $74M | |
| Accum. Depreciation | · | · | · | · | · | $68M | $55M | $50M | $41M | $32M | $24M | $15M | |
| Goodwill | $1.83B | $1.72B | $1.75B | $1.69B | $1.83B | $958M | $920M | $928M | $948M | $894M | $657M | $703M | |
| Intangibles | $4.43B | $4.76B | $5.42B | $5.79B | $7.15B | $2.20B | $2.44B | $2.73B | $2.98B | $3.01B | $1.19B | $1.44B | |
| Other Non-current Assets | $99M | $114M | $67M | $55M | $41M | $26M | $48M | $43M | $16M | $14M | $9M | $16M | |
| Total Assets | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B | $6.54B | $5.54B | $5.20B | $5.12B | $4.80B | $3.33B | $3.34B | |
| Accounts Payable | $122M | $78M | $103M | $91M | $100M | $27M | $46M | $41M | $24M | $22M | $22M | $25M | |
| Accrued Liabilities | $1.03B | $911M | $794M | $803M | $666M | $353M | $270M | $265M | $199M | $193M | $164M | $164M | |
| Current Liabilities | $2.24B | $1.04B | $1.54B | $933M | $809M | $654M | $364M | $345M | $294M | $257M | $227M | $217M | |
| Capital Leases | $51M | $39M | $59M | $72M | $87M | $140M | $151M | $0 | · | · | · | · | |
| Deferred Tax | $594M | $677M | $848M | $944M | $1.30B | $130M | $224M | $309M | $383M | $557M | $283M | $375M | |
| Other Non-current Liabilities | $124M | $87M | $105M | $107M | $117M | $101M | $109M | $219M | $177M | $113M | $69M | $38M | |
| Long-term Debt | $5.36B | $6.11B | $5.71B | $5.72B | $6.05B | $2.09B | $1.61B | $1.60B | $1.58B | $2.03B | $1.19B | $1.34B | |
| Common Stock | $0 | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | |
| Retained Earnings | $646M | $1.13B | $879M | $734M | $830M | $1.16B | $1.07B | $841M | $918M | $529M | $303M | $35M | |
| AOCI | $-569M | $-948M | $-842M | $-1.13B | $-400M | $-134M | $-223M | $-198M | $-141M | $-317M | $-267M | $-122M | |
| Stockholders' Equity | $4.32B | $4.09B | $3.74B | $3.09B | $3.97B | $3.66B | $3.11B | $2.76B | $2.71B | $1.88B | $1.71B | $1.37B | |
| Liabilities + Equity | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B | $6.54B | $5.54B | $5.20B | $5.12B | $4.80B | $3.33B | $3.34B | |
| Shares Outstanding | 61,400,000 | 60,600,000 | 62,255,000 | 63,214,000 | 61,633,000 | 56,171,000 | 56,140,000 | 57,704,000 | 58,898,000 | 59,820,000 | 61,305,000 | 60,643,000 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $42M | $33M | $30M | $30M | $27M | $19M | $15M | $15M | $13M | $12M | $10M | · | |
| Stock-based Comp | $291M | $248M | $227M | $222M | $189M | $121M | $111M | $102M | $107M | $99M | $92M | $70M | |
| Deferred Tax | $-445M | $-208M | $-260M | $-292M | $69M | $-137M | $-237M | $-89M | $-226M | $-41M | $-68M | $-49M | |
| Amort. of Intangibles | $655M | $627M | $608M | $599M | $526M | $260M | $355M | $201M | $152M | $102M | $98M | $127M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | $2M | $2M | |
| Operating Cash Flow | $1.36B | $1.40B | $1.09B | $1.27B | $779M | $900M | $776M | $799M | $693M | $592M | $532M | $408M | |
| CapEx | $59M | $38M | $24M | $29M | $28M | $15M | $40M | $20M | $29M | $10M | $36M | $36M | |
| Investing Cash Flow | $-1.51B | $-508M | $-163M | $-446M | $-5.21B | $-1.01B | $-155M | $-394M | $-269M | $-1.75B | $-2M | $-1.07B | |
| Stock Repurchased | $125M | $311M | $270M | $54.0K | $0 | $147M | $301M | $524M | $99M | $278M | $62M | $42M | |
| Financing Cash Flow | $-873M | $21M | $-305M | $-529M | $3.97B | $528M | $-294M | $-479M | $-409M | $541M | $-214M | $711M | |
| Net Change in Cash | $-1.02B | $907M | $625M | $290M | $-466M | $420M | $328M | $-76M | $20M | $-623M | $305M | $48M | |
| Taxes Paid | $122M | $115M | $178M | · | · | · | · | · | · | · | · | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS (TTM) | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 | $5.23 | $0.93 |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 4.9% | 6.1% | 4.8% | 18.3% | 30.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.3% | 9.6% | 17.5% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 12.5% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | 41.8% | · | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | · | 13.1% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | 35.0% | · | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | · | 20.2% | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B | $2.16B | $1.89B | $1.62B | $1.49B | $1.32B | $1.17B | |
| Net Income TTM | $-356M | $560M | $415M | $-224M | $-330M | $239M | $523M | $447M | $488M | $397M | $330M | $58M | |
| P/E | -29.1 | 14.2 | 20.2 | -44.5 | -23.1 | 39.1 | 16.4 | 17.0 | 16.9 | 17.0 | 26.9 | 176.1 | |
| P / Tangible Book | · | · | · | · | · | 18.3 | · | · | · | · | · | · | |
| Earnings Yield | -3.4% | 7.0% | 5.0% | -2.2% | -4.3% | 2.6% | 6.1% | 5.9% | 5.9% | 5.9% | 3.7% | 0.57% |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.21B | $1.07B | $1.20B | $1.13B | $1.05B | $898M | $1.09B | $1.05B | $1.02B | $902M | $1.01B | $972M | $957M | $893M | $972M | $941M | |
| SG&A Expense | $389M | $353M | $406M | $531M | $358M | $514M | $369M | $326M | $339M | $352M | $396M | $308M | $341M | $298M | $383M | $358M | |
| Operating Expenses | $960M | $732M | $943M | $1.07B | $1.73B | $954M | $897M | $795M | $824M | $836M | $889M | $800M | $800M | $767M | $1.24B | $916M | |
| Operating Income | $248M | $337M | $255M | $58M | $-686M | $-56M | $191M | $260M | $199M | $66M | $122M | $172M | $158M | $126M | $-263M | $25M | |
| Interest Income | $25M | $23M | $20M | $19M | $19M | $28M | $32M | $26M | $25M | $23M | $21M | $19M | $15M | $11M | $7M | $4M | |
| Pretax Income | $211M | $299M | $208M | $9M | $-736M | $-110M | $133M | $201M | $138M | $-2M | $62M | $100M | $82M | $55M | $-340M | $-60M | |
| Income Tax | $18M | $6M | $5M | $-242M | $-17M | $-18M | $-58M | $-15M | $-31M | $12M | $-33M | $-47M | $-24M | $-15M | $-100M | $-43M | |
| Net Income | $193M | $293M | $203M | $251M | $-718M | $-92M | $191M | $215M | $169M | $-15M | $94M | $147M | $104M | $69M | $-241M | $-20M | |
| EPS (Basic) | $3.05 | $4.73 | $3.28 | $4.14 | $-11.74 | $-1.52 | $3.11 | $3.50 | $2.68 | $-0.23 | $1.50 | $2.33 | $1.63 | $1.09 | $-3.86 | $-0.31 | |
| EPS (Diluted) | $2.78 | $4.43 | $3.34 | $4.08 | $-11.74 | $-1.52 | $2.97 | $3.42 | $2.49 | $-0.23 | $1.40 | $2.14 | $1.52 | $1.04 | $-3.85 | $-0.31 | |
| Shares (Basic) | 63,200,000 | 61,900,000 | · | 60,696,000 | 61,200,000 | 61,000,000 | · | 61,414,000 | 62,882,000 | 62,537,000 | · | 63,114,000 | 63,991,000 | 63,494,000 | · | 62,785,000 | |
| Shares (Diluted) | 69,400,000 | 66,100,000 | · | 61,606,000 | 61,200,000 | 61,000,000 | · | 63,174,000 | 69,625,000 | 62,537,000 | · | 71,293,000 | 73,540,000 | 73,771,000 | · | 62,785,000 | |
| EBITDA | $248M | $337M | · | $58M | $-686M | $-56M | · | $260M | $199M | $66M | · | $172M | $158M | $126M | · | $25M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.62B | $1.84B | $1.39B | $1.33B | $1.19B | $1.86B | $2.41B | $2.22B | $1.36B | $1.44B | · | $1.34B | $1.28B | $1.17B | · | $839M | |
| Receivables | $881M | $836M | $831M | $764M | $714M | $653M | $717M | $724M | $698M | $707M | · | $628M | $610M | $624M | · | $601M | |
| Inventory | $443M | $438M | $417M | $483M | $505M | $493M | $480M | $539M | $543M | $577M | · | $612M | $657M | $675M | · | $728M | |
| Prepaid Expense | $200M | $150M | $152M | $147M | $164M | $150M | $177M | $155M | $134M | $123M | · | $110M | $107M | $73M | · | $93M | |
| Other Current Assets | $244M | $285M | $324M | $315M | $298M | $260M | $262M | $354M | $326M | $315M | · | $310M | $272M | $245M | · | $250M | |
| Current Assets | $3.97B | $4.58B | $4.17B | $3.76B | $3.35B | $4.13B | $4.63B | $4.39B | $3.68B | $3.54B | · | $3.25B | $3.01B | $2.78B | · | $2.57B | |
| Goodwill | $1.80B | $1.80B | $1.83B | $1.83B | $1.84B | $1.76B | $1.72B | $1.80B | $1.74B | $1.74B | · | $1.71B | $1.74B | $1.72B | · | $1.59B | |
| Intangibles | $4.03B | $4.20B | $4.43B | $4.57B | $4.77B | $4.72B | $4.76B | $5.14B | $5.08B | $5.24B | · | $5.42B | $5.71B | $5.76B | · | $5.57B | |
| Other Non-current Assets | $86M | $95M | $99M | $103M | $121M | $117M | $114M | $75M | $71M | $71M | · | $76M | $66M | $64M | · | $35M | |
| Total Assets | $11.08B | $11.86B | $11.66B | $11.36B | $10.94B | $11.53B | $12.01B | $12.26B | $11.36B | $11.33B | · | $11.20B | $11.26B | $11.05B | · | $10.38B | |
| Accounts Payable | $128M | $100M | $122M | $152M | $89M | $96M | $78M | $85M | $97M | $81M | · | $110M | $98M | $125M | · | $102M | |
| Accrued Liabilities | $1.03B | $1.02B | $1.03B | $1.00B | $875M | $1.06B | $911M | $859M | $801M | $827M | · | $770M | $748M | $712M | · | $668M | |
| Current Liabilities | $2.23B | $2.25B | $2.24B | $2.27B | $2.07B | $1.22B | $1.04B | $1.03B | $1.56B | $1.56B | · | $1.57B | $945M | $909M | · | $813M | |
| Capital Leases | $44M | $47M | $51M | $53M | $55M | $39M | $39M | $71M | $68M | $56M | · | $62M | $66M | $72M | · | $73M | |
| Deferred Tax | $529M | $548M | $594M | $629M | $682M | $671M | $677M | $792M | $775M | $810M | · | $841M | $911M | $932M | · | $934M | |
| Other Non-current Liabilities | $141M | $162M | $125M | $109M | $94M | $91M | $87M | $111M | $99M | $97M | · | $127M | $127M | $109M | · | $124M | |
| Long-term Debt | $4.35B | $5.35B | $5.36B | $5.36B | $5.36B | $5.37B | $6.11B | $6.11B | $5.71B | $5.71B | · | $5.72B | $5.72B | $5.72B | · | $5.73B | |
| Total Debt | $4.35B | $5.35B | · | $5.36B | $5.36B | $5.37B | · | $6.11B | $5.71B | $5.71B | · | $5.72B | $5.72B | $5.72B | · | $5.73B | |
| Common Stock | $0 | $0 | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | · | $6.0K | $6.0K | $6.0K | · | $6.0K | |
| Retained Earnings | $1.13B | $939M | $646M | $443M | $191M | $1.03B | $1.13B | $936M | $871M | $864M | · | $884M | $812M | $803M | · | $974M | |
| AOCI | $-662M | $-651M | $-569M | $-570M | $-486M | $-786M | $-948M | $-603M | $-888M | $-882M | · | $-1.04B | $-867M | $-980M | · | $-1.62B | |
| Stockholders' Equity | $4.80B | $4.53B | $4.32B | $3.96B | $3.71B | $4.17B | $4.09B | $4.17B | $3.76B | $3.70B | $3.74B | $3.49B | $3.53B | $3.34B | $3.09B | $2.75B | |
| Liabilities + Equity | $11.08B | $11.86B | $11.66B | $11.36B | $10.94B | $11.53B | $12.01B | $12.26B | $11.36B | $11.33B | · | $11.20B | $11.26B | $11.05B | · | $10.38B | |
| Shares Outstanding | 64,800,000 | 62,700,000 | 61,435,000 | 60,740,000 | 60,640,000 | 61,623,000 | 60,631,000 | 60,443,000 | 61,745,000 | 63,028,000 | 62,255,000 | 62,945,000 | · | · | 63,214,000 | · |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $73M | $74M | $71M | $88M | $65M | $68M | $70M | $60M | $57M | $61M | $53M | $56M | $61M | $56M | $62M | $57M | |
| Deferred Tax | $-39M | $-66M | $-63M | $-271M | $-66M | $-44M | $-2M | $-64M | $-75M | $-66M | $-36M | $-79M | $-79M | $-66M | $-145M | $-65M | |
| Amort. of Intangibles | $170M | $172M | $170M | $168M | $162M | $154M | $159M | $157M | $155M | $156M | $152M | $155M | $152M | $150M | $137M | $141M | |
| Operating Cash Flow | $416M | $408M | $363M | $475M | $89M | $430M | $399M | $399M | $331M | $267M | $167M | $307M | $297M | $321M | $342M | $418M | |
| CapEx | $18M | $20M | $17M | $15M | $13M | $14M | $13M | $11M | $7M | $7M | $10M | $4M | $6M | $4M | $9M | $-5M | |
| Investing Cash Flow | $355M | $123M | $-372M | $-328M | $-641M | $-169M | $-193M | $214M | $-257M | $-272M | $102M | $-174M | $-86M | $-5M | $-324M | $5M | |
| Stock Repurchased | · | · | $0 | $0 | · | · | $0 | $150M | · | · | $100M | $74M | · | · | $0 | $0 | |
| Financing Cash Flow | $-994M | $-78M | $75M | $-11M | $-125M | $-814M | $-8M | $246M | $-161M | $-57M | $-100M | $-78M | $-97M | $-30M | $20M | $-289M | |
| Net Change in Cash | $-224M | $452M | $66M | $136M | $-672M | $-551M | $195M | $862M | $-88M | $-63M | $171M | $53M | $114M | $286M | $42M | $128M | |
| Free Cash Flow | · | $388M | · | · | · | $416M | · | · | · | $260M | · | · | · | $317M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 20.5% | 31.5% | · | 5.1% | -65.6% | -6.2% | · | 24.7% | 19.5% | 7.3% | · | 17.7% | 16.5% | 14.1% | · | 2.6% | |
| Net Margin | 16.0% | 27.4% | · | 22.3% | -68.7% | -10.3% | · | 20.4% | 16.5% | -1.6% | · | 15.1% | 10.9% | 7.8% | · | -2.1% | |
| Pretax Margin | 17.5% | 28.0% | · | 0.80% | -70.3% | -12.2% | · | 19.0% | 13.5% | -0.18% | · | 10.2% | 8.5% | 6.2% | · | -6.4% | |
| EBITDA Margin | 20.5% | 31.5% | · | 5.1% | -65.6% | -6.2% | · | 24.7% | 19.5% | 7.3% | · | 17.7% | 16.5% | 14.1% | · | 2.6% | |
| ROA | 1.8% | 2.5% | · | 2.1% | -6.4% | -0.81% | · | 1.8% | 1.5% | -0.13% | · | 1.4% | 0.93% | 0.61% | · | -0.17% | |
| ROE | 4.5% | 6.7% | · | 6.2% | -19.2% | -2.4% | · | 5.6% | 4.6% | -0.42% | · | 4.7% | 3.1% | 2.0% | · | -0.59% | |
| ROIC | 2.5% | 3.3% | · | 17.2% | -7.4% | -0.49% | · | 2.7% | 2.6% | 5.8% | · | 2.8% | 2.2% | 1.8% | · | 0.08% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.8 | 2.0 | · | 1.7 | 1.6 | 3.4 | · | 4.3 | 2.4 | 2.3 | · | 2.1 | 3.2 | 3.1 | · | 3.2 | |
| Quick Ratio | 1.1 | 1.2 | · | 0.9 | 0.9 | 2.1 | · | 2.9 | 1.3 | 1.4 | · | 1.2 | 2.0 | 2.0 | · | 1.8 | |
| Debt / Equity | 0.9 | 1.2 | · | 1.4 | 1.4 | 1.3 | · | 1.5 | 1.5 | 1.5 | · | 1.6 | 1.6 | 1.7 | · | 2.1 | |
| LT Debt / Equity | 0.7 | 1.0 | · | 1.1 | 1.2 | 1.3 | · | 1.5 | 1.4 | 1.4 | · | 1.5 | 1.6 | 1.7 | · | 2.1 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.5 | 1.4 | · | 1.5 | 1.5 | 1.3 | · | 1.6 | 1.6 | 1.4 | · | 1.6 | 1.6 | 1.5 | · | 1.7 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $74.10 | $72.29 | · | $65.18 | $61.12 | $67.75 | · | $69.01 | $60.94 | $58.65 | · | $55.44 | · | · | · | · | |
| Revenue / Share | $17.41 | $16.17 | · | $18.28 | $17.09 | $14.72 | · | $16.70 | $14.70 | $14.42 | · | $13.64 | $13.02 | $12.10 | · | $14.98 | |
| Cash Flow / Share | · | $6.18 | · | · | · | $7.05 | · | · | · | $4.27 | · | · | · | $4.35 | · | · | |
| Cash / Share | $25.00 | $29.41 | · | $21.83 | $19.62 | $30.22 | · | $36.70 | $21.96 | $22.90 | · | $21.22 | · | · | · | · | |
| EPS (TTM) | $14.63 | $0.11 | · | $-6.21 | $-6.87 | $7.36 | · | $7.08 | $5.80 | $4.83 | · | $0.85 | $-1.60 | $-2.57 | · | $-0.37 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.60B | $4.44B | · | $4.16B | $4.09B | $4.06B | · | $3.99B | $3.91B | $3.84B | · | $3.79B | $3.76B | $3.74B | · | $3.58B | |
| Net Income TTM | $941M | $29M | · | $-368M | $-405M | $482M | · | $463M | $395M | $331M | · | $80M | $-87M | $-156M | · | $-19M | |
| Market Cap | $15.61B | $11.85B | · | $8.01B | $6.44B | $7.65B | · | $6.73B | $6.59B | $7.59B | · | $8.15B | · | · | · | · | |
| Enterprise Value | $18.35B | $15.36B | · | $12.04B | $10.61B | $11.16B | · | $10.63B | $10.94B | $11.86B | · | $12.53B | · | · | · | · | |
| P/E | 16.5 | 1718.6 | · | -21.2 | -15.4 | 16.9 | · | 15.7 | 18.4 | 24.9 | · | 152.3 | -77.5 | -56.9 | · | -360.2 | |
| P/S | 3.4 | 2.7 | · | 1.9 | 1.6 | 1.9 | · | 1.7 | 1.7 | 2.0 | · | 2.1 | · | · | · | · | |
| P/B | 3.3 | 2.6 | · | 2.0 | 1.7 | 1.8 | · | 1.6 | 1.8 | 2.1 | · | 2.3 | · | · | · | · | |
| P / Cash Flow | · | 29.0 | · | · | · | 17.8 | · | · | · | 28.4 | · | · | · | · | · | · | |
| EV / Revenue | 4.0 | 3.5 | · | 2.9 | 2.6 | 2.7 | · | 2.7 | 2.8 | 3.1 | · | 3.3 | · | · | · | · | |
| Earnings Yield | 6.1% | 0.06% | · | -4.7% | -6.5% | 5.9% | · | 6.3% | 5.4% | 4.0% | · | 0.66% | -1.3% | -1.8% | · | -0.28% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B |
| Net Income | $-356M | $560M | $415M | $-224M | $-330M |
| Diluted EPS | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 |
No data for this statement
Not enough fundamentals data to build this statement yet.
No data for this statement
Not enough fundamentals data to build this statement yet.
Institutional owners (13F) 686 filers · $15.8B total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
686
Value held
$15.8B
New positions
138
Exited positions
56
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 138 (+32 vs prior Q) | 56 (-21 vs prior Q) | 240 (+24 vs prior Q) | 188 (+19 vs prior Q) | +942K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| BlackRock, Inc. | $1,438,254,453 | 5,968,603 | 9.11% | Shares |
| FMR LLC | $1,110,709,035 | 4,609,326 | 7.04% | Shares |
| VANGUARD GROUP INC | $1,005,914,140 | 5,917,142 | 6.37% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $731,636,247 | 3,036,213 | 4.64% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $657,763,761 | 2,729,650 | 4.17% | Shares |
| Capital World Investors | $650,043,082 | 2,697,610 | 4.12% | Shares |
| FRANKLIN RESOURCES INC | $491,639,148 | 2,040,250 | 3.12% | Shares |
| STATE STREET CORP | $481,895,662 | 1,999,816 | 3.05% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $412,909,300 | 1,713,592 | 2.62% | Shares |
| FULLER & THALER ASSET MANAGEMENT, INC. | $394,839,917 | 1,638,544 | 2.50% | Shares |
| Bank of New York Mellon Corp | $380,253,849 | 1,578,013 | 2.41% | Shares |
| AQR CAPITAL MANAGEMENT LLC | $359,935,093 | 1,522,568 | 2.28% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $357,440,125 | 1,483,031 | 2.26% | Shares |
| AMERIPRISE FINANCIAL INC | $292,895,571 | 1,215,523 | 1.86% | Shares |
| JPMORGAN CHASE & CO | $276,634,191 | 1,160,786 | 1.75% | Shares |
| BANK OF AMERICA CORP /DE/ | $273,763,940 | 1,136,091 | 1.73% | Shares |
| CITADEL ADVISORS LLC | $242,578,716 | 1,006,676 | 1.54% | Shares |
| Swedbank AB | $233,281,128 | 968,092 | 1.48% | Shares |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $192,606,598 | 799,297 | 1.22% | Shares |
| MILLENNIUM MANAGEMENT LLC | $184,072,164 | 763,880 | 1.17% | Shares |
| UBS Group AG | $182,381,760 | 756,865 | 1.16% | Shares |
| VICTORY CAPITAL MANAGEMENT INC | $165,478,678 | 686,719 | 1.05% | Shares |
| NORGES BANK | $158,279,458 | 656,843 | 1.00% | Shares |
| MORGAN STANLEY | $151,734,512 | 629,680 | 0.96% | Shares |
| Mariner, LLC | $146,630,968 | 608,615 | 0.93% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $135,442,731 | 562,073 | 0.86% | Shares |
| Allianz Asset Management GmbH | $131,345,759 | 545,071 | 0.83% | Shares |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $129,891,746 | 539,037 | 0.82% | Shares |
| NORTHERN TRUST CORP | $123,222,660 | 511,361 | 0.78% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $111,450,794 | 462,509 | 0.71% | Shares |
| GMT Capital Corp | $109,279,895 | 453,500 | 0.69% | Shares |
| Boston Trust Walden Corp | $106,779,349 | 443,123 | 0.68% | Shares |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $105,278,106 | 436,893 | 0.67% | Shares |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $103,893,734 | 431,148 | 0.66% | Shares |
| TWO SIGMA INVESTMENTS, LP | $96,439,086 | 400,212 | 0.61% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $95,008,929 | 394,277 | 0.60% | Shares |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | $91,259,201 | 378,715 | 0.58% | Shares |
| Nuveen, LLC | $88,051,524 | 365,405 | 0.56% | Shares |
| Sofinnova Investments, Inc. | $88,036,221 | 365,341 | 0.56% | Shares |
| Polaris Capital Management, LLC | $79,270,937 | 328,966 | 0.50% | Shares |
| AMERICAN CENTURY COMPANIES INC | $77,695,234 | 322,427 | 0.49% | Shares |
| GOLDENTREE ASSET MANAGEMENT LP | $70,838,675 | 294,435 | 0.45% | Shares |
| Qube Research & Technologies Ltd | $70,056,003 | 290,725 | 0.44% | Shares |
| GOLDMAN SACHS GROUP INC | $67,434,009 | 279,844 | 0.43% | Shares |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $66,815,854 | 277,279 | 0.42% | Shares |
| Quantinno Capital Management LP | $65,906,960 | 273,506 | 0.42% | Shares |
| BANK OF MONTREAL /CAN/ | $58,329,921 | 242,063 | 0.37% | Shares |
| RAYMOND JAMES FINANCIAL INC | $55,096,752 | 228,645 | 0.35% | Shares |
| Tri Locum Partners LP | $53,427,868 | 221,720 | 0.34% | Shares |
| Invesco Ltd. | $50,427,310 | 209,268 | 0.32% | Shares |
Activists & 5%+ owners 6 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Jazz Pharmaceuticals Public Limited Company, Jazz Financing I Limited, Jazz Investments II Limited, Jazz Pharmaceuticals Italy S.p.A. ×4 filings | June 20, 2014 | · | Initial filing | · | SEC |
| KKR JP LLC, KKR Millennium Fund L.P., KKR Associates Millennium L.P., KKR Millennium GP LLC, KKR Fund Holdings L.P., KKR Fund Holdings GP Limited, KKR Group Holdings L.P., KKR Group Limited, KKR & Co. L.P., KKR Management LLC, KKR JP III LLC, KKR Partners III, L.P., KKR III GP LLC, Henry R. Kravis, George R. Roberts ×3 filings | March 12, 2013 | · | Initial filing | · | SEC |
| Longitude Capital Partners, LLC, Longitude Venture Partners, L.P., Longitude Capital Associates, L.P., Patrick G. Enright, Juliet Tammenoms Bakker ×3 filings | March 14, 2012 | · | Initial filing | Capital structure | SEC |
| Longitude Capital Partners, LLC (2), Longitude Venture Partners, L.P. (2), Longitude Capital Associates, L.P. (2), Patrick G. Enright (2), Juliet Tammenoms Bakker (2) ×3 filings | Sept. 30, 2011 | · | Initial filing | · | SEC |
| Azur Pharma Limited | Sept. 28, 2011 | · | Initial filing | M&A / sale | SEC |
| Jazz Pharmaceuticals, Inc., KKR Millennium Fund L.P., KKR Associates Millennium L.P., KKR Millennium GP LLC, KKR Partners III, L.P., KKR III GP LLC, KKR JP LLC, KKR JP III LLC | April 28, 2005 | · | Initial filing | M&A / sale | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 56 insiders · 18 officers · 20 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Renee D Gala | President & CEO | Sept. 8, 2026 S | 143,394 | 0 | 1 | $-486,060 |
| Philip L Johnson | EVP & Chief Financial Officer | June 30, 2026 F | 56,431 | 0 | 0 | $0 |
| Matthew P. Young | EVP & CFO | March 6, 2019 S | 36,200 | 0 | 0 | $0 |
| Daniel N Swisher JR | President and COO | March 5, 2023 F | 55,014 | 0 | 0 | $0 |
| Christopher J. Tovey | EVP, COO & Managing Director E | July 5, 2022 M | 14,663 | 0 | 0 | $0 |
| Russell J. Cox | EVP & COO | Dec. 11, 2017 M | 102,821 | 0 | 0 | $0 |
| Neena M Patil | EVP & Chief Legal Officer | Sept. 10, 2026 S | 47,671 | 0 | 14 | $-11,500,359 |
| Mary Elizabeth Henderson | SVP, Technical Operations | Sept. 8, 2026 F | 23,815 | 0 | 2 | $-1,418,523 |
| Robert Iannone | EVP, Global Head of R&D & CMO | Aug. 27, 2026 M | 65,686 | 0 | 7 | $-20,411,738 |
| Samantha Pearce | EVP, Chief Commercial Officer | Aug. 5, 2026 F | 47,131 | 0 | 1 | $-1,625,977 |
| Patricia Carr | SVP, Chief Accounting Officer | March 9, 2026 S | 6,512 | 0 | 7 | $-2,458,091 |
| Kim Sablich | EVP, GM of U.S. | June 5, 2023 D | 28,478 | 0 | 0 | $0 |
| Finbar Larkin | SVP, Technical Operations | March 6, 2023 M | 21,779 | 0 | 0 | $0 |
| MILLER MICHAEL PATRICK | EVP, US Commercial | March 12, 2020 S | 22,118 | 0 | 0 | $0 |
| Paul Treacy | SVP, Technical Operations | Aug. 12, 2019 S | 16,418 | 0 | 0 | $0 |
| Iain Mcgill | SVP, Europe & Rest of World | March 5, 2019 F | 24,938 | 0 | 0 | $0 |
| Karen J Wilson | SVP, Finance & PAO | March 5, 2019 F | 18,385 | 0 | 0 | $0 |
| Suzanne Sawochka Hooper | EVP & General Counsel | Feb. 27, 2019 M | 39,738 | 0 | 0 | $0 |
| Bruce C Cozadd | Director | Sept. 1, 2026 S | 351,875 | 0 | 21 | $-27,147,106 |
| Patrick Kennedy | Director | Aug. 31, 2026 F | 6,452 | 0 | 0 | $0 |
| Mark Douglas Smith | Director | Aug. 31, 2026 F | 9,579 | 0 | 1 | $-266,746 |
| Jennifer E. Cook | Director | Aug. 31, 2026 F | 10,736 | 0 | 0 | $0 |
| Laura Hamill | Director | Aug. 31, 2026 F | 6,832 | 0 | 0 | $0 |
| Heather Ann Mcsharry | Director | Aug. 31, 2026 F | 18,199 | 0 | 2 | $-1,089,119 |
| Rick E Winningham | Director | Aug. 31, 2026 F | 9,466 | 0 | 2 | $-1,656,873 |
| Patrick G. Enright | Director | Aug. 31, 2026 F | 21,278 | 0 | 0 | $0 |
| Ted W Love | Director | Aug. 31, 2026 F | 2,389 | 0 | 0 | $0 |
| Norbert G Riedel | Director | Aug. 31, 2026 F | 6,923 | 0 | 1 | $-655,680 |
| Seamus Mulligan | Director | Aug. 5, 2026 A | 1,184,633 | 0 | 0 | $0 |
| Anne Oriordan | Director | Aug. 8, 2025 F | 16,500 | 0 | 0 | $0 |
| Peter Gray | Director | Aug. 14, 2023 S | 16,068 | 0 | 0 | $0 |
| Catherine A. Sohn | Director | Aug. 14, 2023 S | 14,868 | 0 | 0 | $0 |
| Elmar Schnee | Director | Aug. 5, 2021 S | 8,270 | 0 | 0 | $0 |
| Paul L Berns | Director | Aug. 5, 2021 S | 8,290 | 0 | 0 | $0 |
| Bryan C Cressey | Director | March 9, 2012 S | 27,631 | 0 | 0 | $0 |
| Zilkha M Nathaniel | Director | March 10, 2011 A | · | 0 | 0 | $0 |
| Alexander E Albert | Director | Aug. 15, 2008 A | · | 0 | 0 | $0 |
| Patel Jaimin | Director | Aug. 15, 2007 A | · | 0 | 0 | $0 |
| Kenneth W O'Keefe | · | Dec. 2, 2025 F | 25,811 | 0 | 0 | $0 |
| Karen L. Smith | · | March 5, 2018 F | 28,474 | 0 | 0 | $0 |
| Jeffrey K Tobias | · | March 5, 2015 F | 38,484 | 0 | 0 | $0 |
| Fintan Keegan | · | July 8, 2014 M | 31,750 | 0 | 0 | $0 |
| Kathryn E Falberg | · | March 5, 2014 F | 133,387 | 0 | 0 | $0 |
| James C Momtazee | · | Aug. 13, 2013 S | 17,315 | 0 | 0 | $0 |
| Carol A Gamble | · | March 9, 2012 S | 32,213 | 0 | 0 | $0 |
| Alan Sebulsky | · | March 9, 2012 S | 54,355 | 0 | 0 | $0 |
| Samuel D Colella | · | Jan. 11, 2012 M | 38,347 | 0 | 0 | $0 |
| Michael W Michelson | · | Jan. 11, 2012 M | 13,885 | 0 | 0 | $0 |
| Mark G. Eller | · | Aug. 13, 2011 M | 4,151 | 0 | 0 | $0 |
| Michael A. Desjardin | · | Aug. 13, 2011 M | 14,574 | 0 | 0 | $0 |
| Janne Lt Wissel | · | May 31, 2011 J | 48,544 | 0 | 0 | $0 |
| Joan Colligan | · | Nov. 30, 2010 J | 14,424 | 0 | 0 | $0 |
| Robert M Myers | · | Nov. 30, 2010 J | 156,898 | 0 | 0 | $0 |
| James B Tananbaum | · | Aug. 25, 2010 A | 21,366 | 0 | 0 | $0 |
| Samuel R Saks | · | Jan. 21, 2009 A | 358,868 | 0 | 0 | $0 |
| Matthew K Fust | · | Nov. 28, 2008 J | 58,948 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 62 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| IHE · iShares Trust | 3.45% | 232,236 SH | Sept. 11, 2026 | Daily |
| PJP · Invesco Exchange-Traded Fund Trust | 2.85% | 68,707 SH | Oct. 1, 2026 | Daily |
| XMMO · Invesco Exchange-Traded Fund Trust | 2.31% | 699,006 SH | Oct. 1, 2026 | Daily |
| PTH · Invesco Exchange-Traded Fund Trust | 1.69% | 26,762 SH | Oct. 1, 2026 | Daily |
| PILL · Direxion Shares ETF Trust | 1.25% | 1,023 NS | July 31, 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.98% | 4,592 SH | Oct. 1, 2026 | Daily |
| RFG · Invesco Exchange-Traded Fund Trust | 0.96% | 13,808 SH | Oct. 1, 2026 | Daily |
| IVOG · VANGUARD ADMIRAL FUNDS | 0.79% | 61,910 SH | Aug. 19, 2026 | Daily |
| PDP · Invesco Exchange-Traded Fund Trust | 0.58% | 36,818 SH | Oct. 1, 2026 | Daily |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0.58% | 14,802 NS | July 31, 2026 | N-PORT |
| NUSC · Nushares ETF Trust | 0.54% | 27,352 NS | July 31, 2026 | N-PORT |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0.49% | 8,679 SH | Oct. 1, 2026 | Daily |
| IVOO · VANGUARD ADMIRAL FUNDS | 0.41% | 101,353 SH | Aug. 19, 2026 | Daily |
| MIDU · Direxion Shares ETF Trust | 0.34% | 921 NS | July 31, 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0.32% | 11,363 SH | Aug. 19, 2026 | Daily |
| VBR · VANGUARD INDEX FUNDS | 0.31% | 867,777 SH | Aug. 19, 2026 | Daily |
| VFMF · VANGUARD WELLINGTON FUND | 0.28% | 8,083 SH | Aug. 19, 2026 | Daily |
| DFAS · Dimensional ETF Trust | 0.28% | 168,574 NS | July 31, 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0.24% | 19,561 SH | Aug. 19, 2026 | Daily |
| IYH · iShares Trust | 0.23% | 34,871 SH | Sept. 11, 2026 | Daily |
| ESML · iShares Trust | 0.22% | 25,740 SH | Sept. 11, 2026 | Daily |
| DFAT · Dimensional ETF Trust | 0.22% | 123,193 NS | July 31, 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.20% | 166,548 SH | Aug. 19, 2026 | Daily |
| SMMD · iShares Trust | 0.20% | 31,945 SH | Sept. 11, 2026 | Daily |
| RWK · Invesco Exchange-Traded Fund Trust … | 0.18% | 9,978 SH | Oct. 1, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.17% | 719,903 SH | Aug. 19, 2026 | Daily |
| VB · VANGUARD INDEX FUNDS | 0.17% | 1,366,973 SH | Aug. 19, 2026 | Daily |
| IWS · iShares Trust | 0.14% | 88,598 SH | Sept. 11, 2026 | Daily |
| WSML · iShares Trust | 0.13% | 3,647 SH | Sept. 11, 2026 | Daily |
| IWR · iShares Trust | 0.11% | 244,305 SH | Sept. 11, 2026 | Daily |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0.09% | 3,138 SH | Oct. 1, 2026 | Daily |
| XT · iShares Trust | 0.09% | 13,710 SH | Sept. 11, 2026 | Daily |
| DFAC · Dimensional ETF Trust | 0.08% | 147,012 NS | July 31, 2026 | N-PORT |
| DFUV · Dimensional ETF Trust | 0.08% | 45,748 NS | July 31, 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.05% | 7,084 NS | July 31, 2026 | N-PORT |
| IUSG · iShares Trust | 0.04% | 55,258 SH | Sept. 11, 2026 | Daily |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0.04% | 36,014 SH | Aug. 19, 2026 | Daily |
| IWD · iShares Trust | 0.04% | 133,301 SH | Sept. 11, 2026 | Daily |
| DSI · iShares Trust | 0.04% | 8,411 SH | Sept. 11, 2026 | Daily |
| PRF · Invesco Exchange-Traded Fund Trust | 0.04% | 15,040 SH | Oct. 1, 2026 | Daily |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0.03% | 1,369 SH | Sept. 30, 2026 | Daily |
| DFAU · Dimensional ETF Trust | 0.03% | 13,729 NS | July 31, 2026 | N-PORT |
| DYNF · BlackRock ETF Trust | 0.02% | 39,438 SH | Sept. 11, 2026 | Daily |
| DXUV · Dimensional ETF Trust | 0.02% | 467 NS | July 31, 2026 | N-PORT |
| IYY · iShares Trust | 0.02% | 2,648 SH | Sept. 11, 2026 | Daily |
| DFUS · Dimensional ETF Trust | 0.02% | 17,349 NS | July 31, 2026 | N-PORT |
| ITOT · iShares Trust | 0.02% | 81,293 SH | Sept. 11, 2026 | Daily |
| IWB · iShares Trust | 0.02% | 41,012 SH | Sept. 11, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.02% | 1,892,855 SH | Aug. 19, 2026 | Daily |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0.02% | 9,995 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.02% | 5,021 SH | Aug. 19, 2026 | Daily |
| ESGV · VANGUARD WORLD FUND | 0.02% | 13,490 SH | Aug. 19, 2026 | Daily |
| IWV · iShares Trust | 0.02% | 16,075 SH | Sept. 10, 2026 | Daily |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.01% | 49,429 SH | Aug. 19, 2026 | Daily |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0.01% | 1,238 SH | Oct. 1, 2026 | Daily |
| NEAR · iShares U.S. ETF Trust | 0.00% | 200,000 SH | Sept. 9, 2026 | Daily |
| IJH · iShares Trust | · | 2,201,423 SH | Sept. 11, 2026 | Daily |
| IJK · iShares Trust | · | 363,871 SH | Sept. 11, 2026 | Daily |
| XJH · iShares Trust | · | 8,572 SH | Sept. 8, 2026 | Daily |
| ISCB · iShares Trust | · | 2,820 SH | Sept. 11, 2026 | Daily |
| ISCV · iShares Trust | · | 13,894 SH | Sept. 11, 2026 | Daily |
| SMMV · iShares Trust | · | 4,635 SH | Aug. 19, 2026 | Daily |
JAZZ Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 26 analysts
BUY
Median target
$300.00
+27.3%
7 26.9%
Strong Buy
17 65.4%
Buy
2 7.7%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
22 analysts · 2026-10-03Mean target $294.27 +24.9%
Now
Current price $235.67
Low$225.00
Mean$294.27
High$337.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 3, 2026